Pricing Log in Create free account
Friday 6 November 2026 Export BAX’s income statement to Excel — free account

Baxter International Inc.

BAX Healthcare Medical Instruments & Supplies

Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024.

Revenue
+4.97%
EPS
+731.9%
Free cash flow
+255.6%
Total debt
−9.48%

Quarter to September 2026, against a year earlier

25.73 0.08 +0.31%
Market cap
$13.3B
P/E
0.0×
Fwd P/E
21.3×
Dividend yield
0.16%
F-score
4/9
Altman Z
2.12
Beneish M
−2.67
Dividend safety
0/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Baxter International Inc. 10-Q filed Nov 4, 2025

Fiscal Q3 2025 · Period ended Sep 30, 2025 · Filed · accepted 4:35 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2025: 7 added · 4 removed · 77 modified; 20 with only figures updated; 1 moved without change

  1. Removed · COMPLETED STRATEGIC ACTIONS

    In mid-2022, our Board of Directors authorized a strategic review of our business portfolio, with the goal of increasing stockholder value. As part of that review process, we identified and evaluated a range of potential strategic actions, including opportunities for sales and other separation transactions. In January 2023, following the completion of that review, we announced a number of planned strategic actions, as discussed below, which were intended to enhance our operational effectiveness, accelerate innovation and drive additional stockholder value. We completed the last of these strategic actions on January 31, 2025 in connection with the sale of our Kidney Care business.